文献速递心脑血管急症重症综合管理与镇静镇痛

心脏骤停后昏迷伴脑电图癫痫持续状态患者的肌阵挛:对应脑电图模式、治疗效应与结局

Myoclonus in comatose patients with electrographic status epilepticus after cardiac arrest: Corresponding EEG patterns, effects of treatment and outcomes.
PubMed 文献 · Resuscitation · 2023-02-22
一句话结论心脏骤停后昏迷伴节律性/周期性脑电图模式的患者中,肌阵挛与不良结局及不连续/抑制性脑电图背景相关,但不能单独预测不良结局,且不影响抗癫痫药物的疗效。

该研究为TELSTAR随机试验的事后分析,纳入荷兰和比利时11个ICU的157例心脏骤停后昏迷、持续脑电图监测显示节律性/周期性脑电图模式(RPPs)的成人患者,比较抗癫痫药物与无抗癫痫药物(均在标准治疗基础上)的效应。98例(63%)在纳入时存在肌阵挛;肌阵挛与任何特定RPP类型无关,但与连续性脑电图背景模式概率较低相关(有肌阵挛48% vs 无肌阵挛75%,OR 0.31;95%CI 0.16-0.64),且与RPPs更早出现相关(心脏骤停后24小时内出现RPPs:24% vs 9%,OR 3.86;95%CI 1.64-9.11)。肌阵挛与3个月不良神经结局相关但并非绝对(不良结局96% vs 82%,p=0.004)。抗癫痫药物未改善结局,无论有无肌阵挛(干预组良好结局6% vs 对照组2%,OR 0.33;95%CI 0.03-3.32)。作者认为肌阵挛的存在不能预测不良结局而不出现假阳性。

要点

  • 心脏骤停后昏迷伴RPPs的患者中63%(98/157)存在肌阵挛,肌阵挛与不连续性或抑制性脑电图背景相关(48% vs 75%,OR 0.31;95%CI 0.16-0.64)。
  • 肌阵挛与RPPs更早出现相关:心脏骤停后24小时内出现RPPs者中有肌阵挛24% vs 无肌阵挛9%(OR 3.86;95%CI 1.64-9.11)。
  • 肌阵挛与3个月不良神经结局相关但并非绝对:有肌阵挛者不良结局96% vs 无肌阵挛者82%(p=0.004)。
  • 抗癫痫药物未改善结局,无论有无肌阵挛:干预组良好结局6% vs 对照组2%(OR 0.33;95%CI 0.03-3.32)。
  • 作者认为肌阵挛的存在不能预测不良结局而不出现假阳性。

适用人群与场景

  • 心脏骤停后昏迷的成人患者,持续脑电图监测显示节律性和周期性脑电图模式(RPPs),来自荷兰和比利时11个ICU。
  • TELSTAR试验的事后分析人群,共157例。

处置流程与药物剂量

  • 在标准治疗基础上给予抗癫痫药物 vs 不给抗癫痫药物(TELSTAR试验干预),抗癫痫药物未改善结局(干预组良好结局6% vs 对照组2%,OR 0.33;95%CI 0.03-3.32),无论有无肌阵挛。

研究设计与关键结果

  • 研究类型:TELSTAR前瞻性随机试验的事后分析;样本量157例;11个ICU(荷兰和比利时);人群为心脏骤停后昏迷伴RPPs的成人患者;干预为抗癫痫药物 vs 无抗癫痫药物(均在标准治疗基础上)。
  • 98例(63%)在纳入时存在肌阵挛;肌阵挛与任何特定RPP类型无关。
  • 肌阵挛与连续性脑电图背景模式概率较低相关:有肌阵挛48% vs 无肌阵挛75%(OR 0.31;95%CI 0.16-0.64)。
  • 肌阵挛与RPPs更早出现相关:心脏骤停后24小时内出现RPPs者中有肌阵挛24% vs 无肌阵挛9%(OR 3.86;95%CI 1.64-9.11)。
  • 肌阵挛与3个月不良神经结局相关但并非绝对:有肌阵挛者不良结局96% vs 无肌阵挛者82%(p=0.004)。
  • 抗癫痫药物未改善结局,无论有无肌阵挛:干预组良好结局6% vs 对照组2%(OR 0.33;95%CI 0.03-3.32)。

证据类型、等级与局限

  • 证据类型:前瞻性随机试验(TELSTAR)的事后分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为肌阵挛的存在不能预测不良结局而不出现假阳性,临床决策中不应仅凭肌阵挛判断预后。
  • 抗癫痫药物未改善结局,无论有无肌阵挛,不支持仅因肌阵挛存在而给予抗癫痫药物以改善结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To clarify the significance of any form of myoclonus in comatose patients after cardiac arrest with rhythmic and periodic EEG patterns (RPPs) by analyzing associations between myoclonus and EEG pattern, response to anti-seizure medication and neurological outcome.

DESIGN: Post hoc analysis of the prospective randomized Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation (TELSTAR) trial.

SETTING: Eleven ICUs in the Netherlands and Belgium.

PATIENTS: One hundred and fifty-seven adult comatose post-cardiac arrest patients with RPPs on continuous EEG monitoring.

INTERVENTIONS: Anti-seizure medication vs no anti-seizure medication in addition to standard care.

MEASUREMENTS AND MAIN RESULTS: Of 157 patients, 98 (63%) had myoclonus at inclusion. Myoclonus was not associated with one specific RPP type. However, myoclonus was associated with a smaller probability of a continuous EEG background pattern (48% in patients with vs 75% without myoclonus, odds ratio (OR) 0.31; 95% confidence interval (CI) 0.16-0.64) and earlier onset of RPPs (24% vs 9% within 24 hours after cardiac arrest, OR 3.86;95% CI 1.64-9.11). Myoclonus was associated with poor outcome at three months, but not invariably so (poor neurological outcome in 96% vs 82%, p = 0.004). Anti-seizure medication did not improve outcome, regardless of myoclonus presence (6% good outcome in the intervention group vs 2% in the control group, OR 0.33; 95% CI 0.03-3.32).

CONCLUSIONS: Myoclonus in comatose patients after cardiac arrest with RPPs is associated with poor outcome and discontinuous or suppressed EEG. However, presence of myoclonus does not interact with the effects of anti-seizure medication and cannot predict a poor outcome without false positives.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Nutma S, Ruijter BJ, Beishuizen A, et al. Myoclonus in comatose patients with electrographic status epilepticus after cardiac arrest: Corresponding EEG patterns, effects of treatment and outcomes. Resuscitation. 2023. PMID: 36822459. doi:10.1016/j.resuscitation.2023.109745

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。